258 related articles for article (PubMed ID: 31148594)
1. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
[TBL] [Abstract][Full Text] [Related]
2. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 in colon cancer.
Nakayama M; Oshima M
J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
6. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.
Vinall RL; Chen JQ; Hubbard NE; Sulaimon SS; Shen MM; Devere White RW; Borowsky AD
Dis Model Mech; 2012 Nov; 5(6):914-20. PubMed ID: 22563073
[TBL] [Abstract][Full Text] [Related]
7. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.
Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR
Am J Pathol; 2013 Apr; 182(4):1391-9. PubMed ID: 23499052
[TBL] [Abstract][Full Text] [Related]
8. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
[TBL] [Abstract][Full Text] [Related]
9. Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
van Miltenburg MH; van Nimwegen MJ; Tijdens I; Lalai R; Kuiper R; Klarenbeek S; Schouten PC; de Vries A; Jonkers J; van de Water B
Br J Cancer; 2014 May; 110(11):2747-55. PubMed ID: 24809783
[TBL] [Abstract][Full Text] [Related]
10. TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
Akeno N; Reece AL; Callahan M; Miller AL; Kim RG; He D; Lane A; Moulton JS; Wikenheiser-Brokamp KA
Mol Cancer Ther; 2017 Dec; 16(12):2913-2926. PubMed ID: 28847987
[TBL] [Abstract][Full Text] [Related]
11. Combined Mutation of
Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
[TBL] [Abstract][Full Text] [Related]
12. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
13. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
14. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
[TBL] [Abstract][Full Text] [Related]
15. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage.
Wijnhoven SW; Speksnijder EN; Liu X; Zwart E; vanOostrom CT; Beems RB; Hoogervorst EM; Schaap MM; Attardi LD; Jacks T; van Steeg H; Jonkers J; de Vries A
Cancer Res; 2007 May; 67(10):4648-56. PubMed ID: 17510390
[TBL] [Abstract][Full Text] [Related]
16. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.
Ren YA; Mullany LK; Liu Z; Herron AJ; Wong KK; Richards JS
Cancer Res; 2016 Apr; 76(8):2206-18. PubMed ID: 26964623
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFβ Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors.
Wang D; Nakayama M; Hong CP; Oshima H; Oshima M
Cancer Res; 2024 Jan; 84(1):56-68. PubMed ID: 37851521
[TBL] [Abstract][Full Text] [Related]
19. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
Dibra D; Gagea M; Qi Y; Chau GP; Su X; Lozano G
Cancer Res Commun; 2023 Dec; 3(12):2640-2652. PubMed ID: 38047594
[TBL] [Abstract][Full Text] [Related]
20. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
